Gainesville, FL Clinical Trials Report — July 2026

Gainesville participants should act now if they are considering a study scheduled to close within the next 90 days. The city has 27 recruiting trials approaching their enrollment windows, including 9 that accept healthy volunteers. Gainesville currently offers 539 recruiting trials across 174 research facilities, so there are many alternatives, but enrollment may end before a listed closing date if a study reaches its target.

Closing-soon studies create the clearest immediate opportunity

The conditions represented among Gainesville’s closing-soon trials are varied. Sepsis leads with 2 studies, while the remaining reported categories have one study each. People affected by these conditions, or caregivers searching for options, should contact study teams promptly to confirm whether local enrollment is still available:

• Sepsis (2 trials)
• Aging well (1 trial)
• Bronchopulmonary dysplasia (1 trial)
• Alcohol use and alcohol consumption (2 trials combined)
• Becker muscular dystrophy (1 trial)
• Breast cancer (1 trial)
• Cancer, therapy-related (1 trial)
• Cardiovascular diseases (1 trial)
• Cerebral palsy (1 trial)

Healthy volunteers have fewer time-sensitive choices: 9 of the closing-soon studies accept healthy participants, compared with 72 healthy-volunteer trials recruiting in Gainesville overall. Eligibility can depend on age, medical history, medications, laboratory results, and study-specific requirements, so interested volunteers should inquire before traveling to a site.

New late-stage study at the University of Florida

Gainesville opened 3 new trials in July, down from 4 in May and following 4 new openings in June. The July additions include two device studies and one drug study, covering muscular dystrophy, metabolic abnormalities, asthma, and weight-related conditions. None of the three new trials accepts healthy volunteers.

The most notable opening is NCT07678775, a Phase 3 open-label extension study sponsored by ML Bio Solutions, Inc. It evaluates BBP-418, also called ribitol, in people with limb-girdle muscular dystrophy type 2I/R9 who previously participated in the Fortify study. The planned enrollment is 107 participants. Because this is a rollover extension, eligibility is focused on people from the earlier study rather than the general population.

• NCT07678775: Phase 3 open-label extension of BBP-418 (ribitol) for limb-girdle muscular dystrophy type 2I/R9; sponsored by ML Bio Solutions, Inc.; 107 planned participants.
• A new device study sponsored by Spiro Medical, Inc. for moderate to severe asthma.
• A University of Florida-sponsored study involving metabolic abnormalities, obesity and overweight, or obese adolescents.

The new-trial mix is primarily industry-sponsored: 2 openings come from industry sponsors and 1 is categorized as other. Two new studies include children, and two include older adults. No July opening is limited to women or men. Families considering a pediatric study should ask about age ranges, guardian consent, visit schedules, and whether the child must have a specific diagnosis.

University of Florida sites offer the broadest access

The University of Florida is the dominant research hub in Gainesville, with 190 recruiting trials. UF Health Cancer Institute - Gainesville follows with 57, giving local cancer patients a particularly important place to begin their search. Other University of Florida and Veterans Health System facilities add options across neurology, oncology, cardiovascular research, respiratory disease, and other specialties.

• University of Florida (190 trials)
• UF Health Cancer Institute - Gainesville (57 trials)
• Research Site (18 trials)
• University of Florida Health (13 trials)
• North Florida/South Georgia Veterans Health System, Gainesville (11 trials)
• Malcom Randall Veterans Administration Medical Center (9 trials)
• University of Florida College of Medicine (8 trials)
• UF Health Shands Hospital (7 trials)
• UF Health (7 trials)
• Vitreo Retinal Associates (7 trials)
• Norman Fixel Institute for Neurological Diseases (6 trials)
• University of Florida Shands Hospital (6 trials)

These facility names can overlap within the broader University of Florida and UF Health network, but they indicate where local research activity is concentrated. Patients may want to search the University of Florida system first, then check UF Health Cancer Institute for oncology studies and the Veterans facilities for eligible veterans and other qualifying adults.

More Florida options for people willing to travel

Gainesville residents who do not find a suitable local study can broaden their search across Florida. Miami has 15 recruiting trials in the nearby-city comparison, followed by Tampa with 13 and Orlando with 7. Additional options appear in Coral Gables, Fort Myers, Jacksonville, and Hollywood, with 5 trials each, and Miami Lakes with 4.

New openings have slowed from the 12 trials recorded in February and 10 in March to 3 in July. The recent pattern was 5 in April, 8 in May, 4 in June, and 3 in July, with three also listed for August. As Gainesville’s active research base remains large, July’s closing deadlines make early contact the best way to preserve access while new studies continue to develop.